Fig. 2
From: MED12 mutation as a potential predictive biomarker for immune checkpoint inhibitors in pan-cancer
Relationship between MED12 mutation and enhanced tumor immunity. A Comparison of the TMB between the MED12-Mut and MED12-Wt groups from the WES cohorts. B Comparison of the TMB between the MED12-Mut and MED12-Wt groups from the MSKCC cohort. C Comparison of the TMB between the MED12-Mut and MED12-Wt groups from the TCGA cohort. D Comparison of the TNB between the MED12 mutant and wildtype groups from the WES cohorts. E Comparison of DNA damage-related gene (DDR) set variants between MED12-Mut and MED12-Wt patients in TCGA cohort. F Comparison of tumor-infiltrating immune cells abundance in MED12-Mut and MED12-Wt pan-cancers. *P < 0.05; **P < 0.01; ***P < 0.001; ns: P > 0.05